CDXS
Price
$2.71
Change
+$0.02 (+0.74%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
244.97M
57 days until earnings call
Intraday BUY SELL Signals
LXRX
Price
$1.84
Change
-$0.05 (-2.65%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
837.31M
57 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CDXS vs LXRX

Header iconCDXS vs LXRX Comparison
Open Charts CDXS vs LXRXBanner chart's image
CDXS vs LXRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CDXS vs. LXRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and LXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2026
Stock price -- (CDXS: $2.69 vs. LXRX: $1.88)
Brand notoriety: CDXS and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 42% vs. LXRX: 124%
Market capitalization -- CDXS: $244.97M vs. LXRX: $837.31M
CDXS [@Biotechnology] is valued at $244.97M. LXRX’s [@Biotechnology] market capitalization is $837.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.89B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both CDXS and LXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while LXRX’s TA Score has 6 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 5 bearish.
  • LXRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а +3.65% price change this week, while LXRX (@Biotechnology) price change was -8.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.54%. For the same industry, the average monthly price growth was -1.96%, and the average quarterly price growth was +3.26%.

Reported Earning Dates

CDXS is expected to report earnings on Jul 30, 2026.

LXRX is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (-1.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($837M) has a higher market cap than CDXS($245M). CDXS (65.337) and LXRX (63.913) have similar YTD gains . LXRX has higher annual earnings (EBITDA): -17.44M vs. CDXS (-21.2M). LXRX has more cash in the bank: 171M vs. CDXS (65.1M). LXRX has less debt than CDXS: LXRX (57.7M) vs CDXS (72.9M). CDXS has higher revenues than LXRX: CDXS (78.1M) vs LXRX (69.6M).
CDXSLXRXCDXS / LXRX
Capitalization245M837M29%
EBITDA-21.2M-17.44M122%
Gain YTD65.33763.913102%
P/E RatioN/AN/A-
Revenue78.1M69.6M112%
Total Cash65.1M171M38%
Total Debt72.9M57.7M126%
FUNDAMENTALS RATINGS
CDXS vs LXRX: Fundamental Ratings
CDXS
LXRX
OUTLOOK RATING
1..100
6293
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
3636
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (40) in the Chemicals Specialty industry is in the same range as LXRX (72) in the Biotechnology industry. This means that CDXS’s stock grew similarly to LXRX’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as LXRX (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's SMR Rating (96) in the Biotechnology industry is in the same range as CDXS (99) in the Chemicals Specialty industry. This means that LXRX’s stock grew similarly to CDXS’s over the last 12 months.

LXRX's Price Growth Rating (36) in the Biotechnology industry is in the same range as CDXS (36) in the Chemicals Specialty industry. This means that LXRX’s stock grew similarly to CDXS’s over the last 12 months.

LXRX's P/E Growth Rating (26) in the Biotechnology industry is significantly better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that LXRX’s stock grew significantly faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSLXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 7 days ago
87%
Declines
ODDS (%)
Bearish Trend 13 days ago
86%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 6 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signal:
Gain/Loss:
LXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNWAX103.20N/A
N/A
American Funds New World R1
PSOAX29.21N/A
N/A
JPMorgan Small Cap Value A
IVIPX33.46N/A
N/A
VY® Invesco Equity and Income S2
MCFGX14.86N/A
N/A
BlackRock Capital Appreciation Inv C
SCJIX8.32N/A
N/A
Steward Covered Call Income I

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+0.94%
AXON - CDXS
43%
Loosely correlated
+2.78%
TNYA - CDXS
41%
Loosely correlated
-9.20%
VCYT - CDXS
39%
Loosely correlated
-0.79%
CRBU - CDXS
38%
Loosely correlated
-4.32%
ARRY - CDXS
36%
Loosely correlated
+4.54%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-8.94%
PLRX - LXRX
58%
Loosely correlated
-3.33%
VCYT - LXRX
37%
Loosely correlated
-0.79%
ABOS - LXRX
36%
Loosely correlated
-5.46%
CDXS - LXRX
36%
Loosely correlated
+0.94%
CRBU - LXRX
35%
Loosely correlated
-4.32%
More